ATTRv is a rare autosomal dominant disorder caused by transthyretin
(TTR) mutations. The p.Ala101Val variant has been reported but its phenotype is not fully defined. Characterizing variant‑specific features guides diagnosis.
In this study, researchers in Minsk studied five unrelated probands (aged 64 to 74) with heterozygous
TTR c.302C>T. Comprehensive cardiac imaging, electrophysiology, and neurological exams were performed. Four had cardiomyopathy, while one had arrhythmic events without overt cardiomyopathy. All had neuropathy, two with carpal tunnel syndrome. Bone scintigraphy showed Grade 1 or 2 uptake. One required a pacemaker, later resynchronization. Two developed heart failure and died within one year.
These findings confirm p.Ala101Val causes late‑onset ATTRv with cardiac, arrhythmic, and neurologic features. The reduced scintigraphic sensitivity, also seen in Polish patients, is a pitfall: low uptake does not exclude ATTR. Clinicians should suspect ATTR and order genetic testing when red flags appear, even with equivocal scintigraphy. Genotype‑informed algorithms are needed where this variant may be underrecognized.
The work titled “Clinical phenotypes linked to the p.Ala101Val mutation in the
TTR gene in Belarusian patients with transthyretin amyloidosis”, was published on
Cardiac Research (accepted on May. 13, 2026).
DOI:10.1097/re9.0000000000000018